• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 2, 2020

View Archived Issues
Respiratory-lungs-wireframe

FDA approves Pharmaxis’ Bronchitol for cystic fibrosis as company looks to myelofibrosis

PERTH, Australia – With the approval of cystic fibrosis treatment Bronchitol (mannitol), Sydney-based Pharmaxis Ltd. joins a small group of elite Australian biotech companies to take their drugs all the way to FDA approval. Read More
Natural killer cell

Sanofi acquires natural killer cell platform in $358M Kiadis buyout

DUBLIN – Kiadis Pharma BV has parlayed its €31.9 million (US$37.2 million) stock-based acquisition of Cytosen Therapeutics Inc. last year, which involved an initial outlay of just €14.5 million worth of shares, into a €308 million payday with Sanofi SA. Read More
Cancer-cell-antibody-attack

Jounce tumbles as phase II NSCLC trial readout disappoints

Jounce Therapeutics Inc. has quit enrolling Emerge, an open-label phase II study of its inducible T-cell co-stimulator agonist, vopratelimab, the company’s most advanced candidate. Read More
Venture funding

Formed by former Novartis CEO, Aditum Bio fund looks to target treatment gaps

LONDON – Former CEO of Novartis AG Joe Jimenez is emerging back into the limelight as founder and managing director of Aditum Bio, a new $135 million venture capital fund set up to create five to six companies to take forward early stage compounds in-licensed from pharma. Read More

Icosavax gets a $16.5M boost to study its COVID-19 candidate

A multimillion dollar windfall for Icosavax Inc. will help allow the company to launch a COVID-19 vaccination program using its virus-like particle candidate (VLP), IVX-411, that displays the SAR-CoV-2 receptor-binding domain. Read More
Coronavirus stock market

Biopharma companies hit a rough patch in October

The dramatic increase in COVID-19 infections in Europe and the U.S., combined with information overload surrounding the lead up to the Nov. 3 contentious U.S. presidential election, was more than enough to send investors to the sidelines in October. Read More

Study shows cellular immunity at six months post COVID-19 infection

LONDON – People infected with COVID-19 are likely to have T-cell immunity six months after contracting the virus, according to a U.K. study of 100 subjects who had an asymptomatic or mild to moderate infection. Read More
Microscope and coronavirus illustration

Desperately seeking wellness and immunity in a sea of COVID-19 research

October brought another burgeoning swell of pandemic news with the U.S. granting its first FDA approval for a COVID-19 therapy, a promising vaccine candidate reaching full enrollment in phase III, and the stoppage of several trials due to safety signals. Read More

Haihe nabs second partnership with 3D Biomedicine for non-opioid analgesics

HONG KONG – Haihe Pharmaceutical Co. Ltd. has outsourced the China rights to its non-opioid analgesics candidates, RMX-1001 and RMX-1002, to 3D Biomedicine Science & Technology Co. Ltd. in the latest collaboration between the two companies. Read More

More chemo drugs needed on FDA list

The latest global regulatory news, changes and updates affecting biopharma, including: Canada prepares for resurgence of COVID-19 shortages; Russia sets drug pricing structure. Read More
Cancer-cells-pic.png

NGF: PDAC’s VEGF?

BioWorld looks at translational medicine, including: Revving up cisplatin by targeting Rev7. Read More
ICYMI illustration

ICYMI: Week in review, Oct. 26-30, 2020

A quick look back at top stories. Read More

Appointments and advancements for Nov. 2, 2020

New hires and promotions in the biopharma industry, including: Acousia, Caladrius, Cormedix, Eagle, Horizon, Freeline, Mission, Mogrify, Oryzon, Rallybio, Silence, X4. Read More

Earnings for Nov. 2, 2020

Quarterly snapshots from biopharma companies with marketed products, including: Alkermes, Gilead, Horizon, PTC, Seagen, Vertex. Read More

Financings for Nov. 2, 2020

Biopharmas raising money in public or private financings, including: Carsgen, Corlieve, Cure, Erytech, Mirati, Novartis, Population Health, Regenxbio. Read More

In the clinic for Nov. 2, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Agenus, Aim, Aivita, Aligos, Arcutis, Astrazeneca, Curevac, Daiichi, Eli Lilly, Gritstone, Humanigen, Immunic, Incyte, Jounce, Mindmed, Novartis, Resverlogix, Revimmune, Rhythm, Shionogi, Sun, Symvivo, Tetra, Tiziana, UCB, Ultimovacs. Read More

Other news to note for Nov. 2, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamas, Addex, Amphilix, Astrazeneca, Augmenta, Biospecifics, Blue Water, Calithera, Checkpoint, China Grand Pharmaceutical, CNS Pharmaceuticals, Daewoong, Decibel, Endo, Eurofins, Fusion, Genequantum, Hillstream, Horizon, Indivior, Isofol, Janssen, JT Pharmaceuticals, Mylan, Mymetics, Novavax, Ocuphire, Pfizer, Prevail, Recombinetics, Regulus, Rexahn, Samsung Biologics, Sanofi, Santhera, SK Biopharmaceuticals, Telix, Tempus, TFF, Titan, Zucara. Read More

Regulatory actions for Nov. 2, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: CSL, DBV, Chiesi, Imugene, Innocare, Innovation, Janssen, Neuraly, Pharmaxis, Polarityte, Poseida, Provention, Roche, Senhwa, Taigen. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe